199 related articles for article (PubMed ID: 6139285)
21. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
[TBL] [Abstract][Full Text] [Related]
22. Induction of dopaminergic supersensitivity after a single dose of the neuroleptic isofloxythepin.
Valchár M; Metysová J; Chlebounová J; Dlabac A
Psychopharmacology (Berl); 1982; 76(4):381-4. PubMed ID: 6126896
[TBL] [Abstract][Full Text] [Related]
23. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
[TBL] [Abstract][Full Text] [Related]
24. Chronic haloperidol treatment potentiates apomorphine- and ethanol-induced hypothermia in the rat.
Lai H; Kazi MS; Carino MA; Horita A
Life Sci; 1982 Mar; 30(10):821-6. PubMed ID: 7200179
[TBL] [Abstract][Full Text] [Related]
25. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
Lau YS; Runice C; Dowd F
J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
[TBL] [Abstract][Full Text] [Related]
26. Studies on the mechanism of action of substituted benzamide drugs.
Köhler C; Ogren SO; Fuxe K
Acta Psychiatr Scand Suppl; 1984; 311():125-37. PubMed ID: 6142588
[TBL] [Abstract][Full Text] [Related]
27. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat.
Simpson MD; Jenner P; Marsden CD
Biochem Pharmacol; 1986 Oct; 35(20):3501-6. PubMed ID: 3768037
[TBL] [Abstract][Full Text] [Related]
28. Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists.
Hruska RE
Brain Res Bull; 1986 Mar; 16(3):331-9. PubMed ID: 3708389
[TBL] [Abstract][Full Text] [Related]
29. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
30. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
Frey JM; Morgan WW; Ticku MK; Huffman RD
Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028
[TBL] [Abstract][Full Text] [Related]
31. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat.
Scavone C; De Lucia R; Bernardi MM; Aizenstein ML
Eur J Pharmacol; 1985 May; 112(1):11-6. PubMed ID: 4040467
[TBL] [Abstract][Full Text] [Related]
32. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
[TBL] [Abstract][Full Text] [Related]
33. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
Allen RM; Lane JD; Brauchi JT
Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
[TBL] [Abstract][Full Text] [Related]
34. Chronic treatments with zotepine, thioridazine, and haloperidol affect apomorphine-elicited stereotypic behavior and striatal 3H-spiroperidol binding sites in the rat.
Lai H; Carino MA; Horita A
Psychopharmacology (Berl); 1981; 75(4):388-90. PubMed ID: 6122233
[TBL] [Abstract][Full Text] [Related]
35. Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
Ben-Shachar D; Pinhassi B; Youdim MB
Eur J Pharmacol; 1991 Sep; 202(2):177-83. PubMed ID: 1687031
[TBL] [Abstract][Full Text] [Related]
36. L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
Ferre S; Casas M; Cobos A; Garcia C; Jane F; Grau JM
Psychopharmacology (Berl); 1987; 91(2):254-6. PubMed ID: 3107042
[TBL] [Abstract][Full Text] [Related]
37. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
Apud JA; Masotto C; Ongini E; Racagni G
Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
[TBL] [Abstract][Full Text] [Related]
38. Aging and the regulation of striatal dopaminergic mechanisms in mice.
Randall PK; Severson JA; Finch CE
J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
[TBL] [Abstract][Full Text] [Related]
39. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.
Severson JA; Robinson HE; Simpson GM
Psychopharmacology (Berl); 1984; 84(1):115-9. PubMed ID: 6149590
[TBL] [Abstract][Full Text] [Related]
40. Increased striatal acetylcholine after 14 months cis-flupenthixol treatment in rats suggests functional supersensitivity of dopamine receptors.
Murugaiah K; Mann S; Theodorou AE; Jenner P; Marsden CD
Life Sci; 1982 Jul; 31(2):181-8. PubMed ID: 6889662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
